{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:52:40Z","timestamp":1773251560108,"version":"3.50.1"},"reference-count":35,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1080\/14712598.2024.2423002","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T08:32:26Z","timestamp":1729931546000},"page":"1193-1198","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9123-8900","authenticated-orcid":false,"given":"Denis T.","family":"Balaban","sequence":"first","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7969-8346","authenticated-orcid":false,"given":"Michael","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Meningococcal Reference Unit, UK Health Security Agency, Manchester Royal Infirmary, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique R.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/11795735241231094"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17551-X"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050304"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318248dec1"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awl371"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70076-0"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws109"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.1107"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01068-2"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01726-y"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26626"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11699-x"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0001051192.25521.0b"},{"key":"e_1_3_5_18_1","volume-title":"Ravulizumab [Package Insert]","year":"2018","unstructured":"Ravulizumab [Package Insert]. Alexion Pharmaceuticals, Inc; 2018."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6909a1"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6627e1"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241989"},{"key":"e_1_3_5_22_1","unstructured":"Alexion Pharmaceuticals Inc. Drug safety and risk management advisory committee briefing document for Soliris\u00ae (eculizumab) [internet]. Cheshire (CT); 2014. Available from: https:\/\/pink.citeline.com\/-\/media\/pmbi-old-site\/supporting-documents\/the-pink-sheet-daily\/2014\/november\/soliris_ac_alexion_brfg.pdf"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.002"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"e_1_3_5_25_1","unstructured":"PNH National Service. Meningococcal Infection and Eculizumab\/Complement Inhibitors [Internet]. 2022 [cited 2024 Jul 26]. Available from: https:\/\/www.pnhleeds.co.uk\/professionals\/meningococcal-infection-and-eculizumab-complement-inhibitors\/"},{"key":"e_1_3_5_26_1","unstructured":"Haut Conseil de la sant\u00e9 publique. relatif \u00e0 la prophylaxie des infections bact\u00e9riennes invasives chez les patients trait\u00e9s par inhibiteurs du compl\u00e9ment (\u00e9culizumab ravulizumab pegc\u00e9catoplan) [Internet]. 2022 [cited 2024 Jul 26]. Available from: https:\/\/www.hcsp.fr\/Explore.cgi\/Telecharger?NomFichier=hcspa20220401_prvedesinfeinvachezdespatitraipa.pdf"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002497"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2018.10.015"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1893-23"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2408.180228"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"e_1_3_5_32_1","unstructured":"Inebelizumab [Package Insert]. Viela Bio Inc. 2020."},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25045"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.11.015"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmmb.2022.05.005"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7004a1"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2423002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T06:46:51Z","timestamp":1732862811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2423002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1080\/14712598.2024.2423002"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2423002","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}